Humedix Co., Ltd. (200670.KQ)
KRW 42800.0
(3.38%)
KRW 42800.0
(3.38%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.7 Billion KRW | -92.42% |
| 2022 | 35.63 Billion KRW | 8.88% |
| 2021 | 32.73 Billion KRW | 55.51% |
| 2020 | 21.04 Billion KRW | 1121.52% |
| 2019 | 1.72 Billion KRW | -56.24% |
| 2018 | 3.93 Billion KRW | -60.62% |
| 2017 | 9.99 Billion KRW | -5.69% |
| 2016 | 10.6 Billion KRW | 0.0% |
| 2015 | - KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 2.51 Billion KRW | -6.87% |
| 2024 Q2 | 2.36 Billion KRW | -6.14% |
| 2023 Q3 | 4.57 Billion KRW | -49.21% |
| 2023 FY | 2.7 Billion KRW | -92.42% |
| 2023 Q2 | 8.99 Billion KRW | -52.26% |
| 2023 Q4 | 2.7 Billion KRW | -40.88% |
| 2023 Q1 | 18.84 Billion KRW | -47.12% |
| 2022 FY | 35.63 Billion KRW | 8.88% |
| 2022 Q4 | 35.63 Billion KRW | 0.53% |
| 2022 Q3 | 35.45 Billion KRW | 1.77% |
| 2022 Q2 | 34.83 Billion KRW | 2.34% |
| 2022 Q1 | 34.03 Billion KRW | 3.99% |
| 2021 FY | 32.73 Billion KRW | 55.51% |
| 2021 Q3 | 37.02 Billion KRW | 12.17% |
| 2021 Q4 | 32.73 Billion KRW | -11.59% |
| 2021 Q2 | 33 Billion KRW | 162963.94% |
| 2021 Q1 | 20.24 Million KRW | -2.46% |
| 2020 Q3 | 24.45 Million KRW | 1.98% |
| 2020 FY | 21.04 Billion KRW | 1121.52% |
| 2020 Q4 | 20.75 Million KRW | -15.14% |
| 2020 Q1 | 313.48 Thousand KRW | -78.52% |
| 2020 Q2 | 23.98 Million KRW | 7550.13% |
| 2019 Q4 | 1.45 Million KRW | 7.11% |
| 2019 FY | 1.72 Billion KRW | -56.24% |
| 2019 Q3 | 1.36 Million KRW | -50.38% |
| 2019 Q2 | 2.74 Million KRW | -35.04% |
| 2019 Q1 | 4.22 Million KRW | 7.39% |
| 2018 Q3 | 5.25 Million KRW | -20.0% |
| 2018 FY | 3.93 Billion KRW | -60.62% |
| 2018 Q1 | 8.59 Million KRW | -14.02% |
| 2018 Q4 | 3.93 Million KRW | -25.0% |
| 2018 Q2 | 6.56 Million KRW | -23.66% |
| 2017 FY | 9.99 Billion KRW | -5.69% |
| 2017 Q4 | 9.99 Million KRW | -21.49% |
| 2017 Q1 | 11.36 Million KRW | 7.23% |
| 2017 Q2 | 13.14 Million KRW | 15.63% |
| 2017 Q3 | 12.73 Million KRW | -3.12% |
| 2016 Q4 | 10.6 Million KRW | 0.0% |
| 2016 FY | 10.6 Billion KRW | 0.0% |
| 2016 Q1 | - KRW | 0.0% |
| 2015 FY | - KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 23.72 Billion KRW | 88.614% |
| CMG Pharmaceutical Co., Ltd. | 19.74 Billion KRW | 86.316% |
| Celltrion Pharm, Inc. | 162.52 Billion KRW | 98.338% |
| Huons Global Co., Ltd. | 254.93 Billion KRW | 98.94% |
| DongKook Pharmaceutical Co., Ltd. | 104.74 Billion KRW | 97.421% |
| Enzychem Lifesciences Corporation | 5.65 Billion KRW | 52.241% |
| Boditech Med Inc. | 10.56 Billion KRW | 74.434% |
| EuBiologics Co., Ltd. | 14.77 Billion KRW | 81.719% |
| FutureChem Co.,Ltd | 3.68 Billion KRW | 26.634% |
| Huons Co., Ltd. | 124.61 Billion KRW | 97.832% |
| BNC Korea Co., Ltd. | 737.2 Million KRW | -266.484% |
| AptaBio Therapeutics Inc. | 13.93 Billion KRW | 80.61% |